QUINTESSENTIAL-2
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 3
- Enrollment
- 440 patients (estimated)
- Sponsors
- Juno Therapeutics, a Bristol-Myers Squibb Company
- Tags
- CAR T Cell, GPRC5D, Quadruplet Therapy, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1996
- NCT Identifier
- NCT06615479
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.